EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures
EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures.
“We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases.Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities,” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.
“With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics.
“I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs,” said Mojgan Hossein-Nia, Board Member at Egle Therapeutics.
Michel Detheux, Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).
Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.
Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes.
Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies.
Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Reports a Record AED 14.6 Billion in Revenue for the First Half of 2025 and Approves Dividend Payment of AED 3.1 Billion8.8.2025 18:47:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808832927/en/ Dubai Electricity and Water Authority PJSC reports a record AED 14.6 billion in revenue for the first half of 2025 and approves dividend payment of AED 3.1 billion (Graphic: AETOSWire) “DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highn
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills8.8.2025 16:54:00 EEST | Press release
Sutherland, a global leader in business and digital transformation, has partnered with the Philippine Government to launch a dedicated AI Academy. This strategic initiative supports the Philippine government’s broader efforts to empower the Filipino workforce for an AI-driven future. The AI Academy will offer practical, industry-aligned training designed to equip Filipino professionals with skills to integrate artificial intelligence into their work. It aims to strengthen the country’s talent pool by developing capabilities that are increasingly in demand across sectors, whether as AI specialists, prompt engineers, or cybersecurity professionals. The program will prepare participants to harness AI in driving productivity, advancing innovation, and pursuing high-value opportunities across industries. “This initiative is a vital step toward our goal of building a digitally resilient and inclusive workforce, said President Ferdinand R. Marcos Jr. “By expanding access to training in future
Baraja Appoints IP Pioneer to Lead Global Sale of Spectrum-Scan™ LiDAR IP Assets8.8.2025 16:00:00 EEST | Press release
Baraja Pty Ltd (“Baraja”), the Australian pioneer behind the revolutionary Spectrum‑Scan™ LiDAR architecture, has announced a global initiative to commercialize its full suite of patented LiDAR intellectual property and technical assets. The company has appointed IP Pioneer Group Incas the exclusive worldwide advisor to manage this competitive transaction process. Baraja redefined LiDAR performance through its Spectrum-Scan™ technology—a transformative solid-state architecture that steers the laser beam by tuning its wavelength through a dispersive prism or grating, eliminating moving parts. This breakthrough enables long-range, high-resolution 3D sensing that is inherently immune to alignment drift, sunlight, and multi-LiDAR interference. Having achieved significant technical milestones in LiDAR innovation, Baraja is now strategically evolving its business focus to pursue new frontiers in sensing and perception. This initiative will allow a new commercial partner to capitalize on the
Graanul - Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation8.8.2025 13:54:00 EEST | Press release
Graanul: Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation for Graanul’s: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and, together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and tog
Traka Celebrates 30 Years of Innovation in Intelligent Key and Asset Management8.8.2025 12:00:00 EEST | Press release
Traka, an ASSA ABLOY company and global leader in intelligent key and equipment management solutions, is excited to announce its 30 years of innovation in intelligent key and asset management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808492250/en/ Traka is celebrating its 30th anniversary this year after its inception in 1995. What began as a custom solution for British Airways has grown into a global leader in intelligent key and asset management. Traka, now celebrating its 30th anniversary, is marking three decades of innovation, expansion, and impact across more than 30 industries worldwide. In 1995, Traka’s founder, John Kent, responded to a unique challenge: British Airways needed a secure and trackable way to manage critical keys, something the market didn’t yet offer. Kent built the first Traka key cabinet, setting the foundation for what would become a new category in access management. That first electronic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom